Successful treatment of severe psoriasis relapse with secukinumab (interleukin 17 A inhibitor) after abrupt brodalumab (interleukin 17 receptor inhibitor) discontinuation: A retrospective study evaluating long-term efficacy and safety

Publication date: October 2018

Source: Journal of the American Academy of Dermatology, Volume 79, Issue 4

Author(s): Abdallah Khemis, Awatef Kelati, Henri Montaudié, Jean-Philippe Lacour, Thierry Passeron